Summary of Clinical Use

Crenezumab may have potential for the treatment of Alzherimer's disease (AD). In phase 1 clinical trial plasma amyloid β (Aβ) levels correlated with serum drug concentration and in contrast to clinical trials with gantenerumab, crenezumab did not cause vasogenic edema. A Phase 2 trial in asymptomatic patients carrying the autosomal dominant PSEN1E280A mutation which causes early onset AD is underway. NCT01343966 (ABBY study, Phase 2) evaluating efficacy and safety of crenezumab in patients with mild to moderate AD has been completed, as has NCT01397578 which was evaluating the impact of crenezumab on Aβ levels and relevant biomarkers, but results have not yet been published (Dec 2014). NCT01723826 is an extension study in the patients with mild to moderate AD, who have received crenezumab as part of the NCT01397578 and NCT01343966 trials.

Mechanism Of Action and Pharmacodynamic Effects

Anti-Aβ antibodies are hypothesised to have the potential to clear Aβ from the circualtion and prevent/reduce the formation of amyloid plaques.